1. Home
  2. AIRI vs VTGN Comparison

AIRI vs VTGN Comparison

Compare AIRI & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Industries Group

AIRI

Air Industries Group

HOLD

Current Price

$2.67

Market Cap

12.3M

Sector

Industrials

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.24

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRI
VTGN
Founded
1979
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
10.8M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
AIRI
VTGN
Price
$2.67
$0.24
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$0.90
AVG Volume (30 Days)
25.9K
603.0K
Earning Date
05-14-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
24.39
N/A
EPS
N/A
N/A
Revenue
$47,921,000.00
N/A
Revenue This Year
$6.43
$124.49
Revenue Next Year
N/A
$353.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.30
$0.20
52 Week High
$3.95
$5.14

Technical Indicators

Market Signals
Indicator
AIRI
VTGN
Relative Strength Index (RSI) 49.42 41.03
Support Level $2.55 $0.23
Resistance Level $2.76 $0.32
Average True Range (ATR) 0.09 0.01
MACD 0.01 0.00
Stochastic Oscillator 68.18 28.46

Price Performance

Historical Comparison
AIRI
VTGN

About AIRI Air Industries Group

Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: